Jenburkt Pharmaceuticals Ltd. – Company Report
1. Company Overview
Jenburkt Pharmaceuticals Ltd., founded in 1985 and headquartered in Mumbai, is a trusted Indian pharmaceutical company engaged in the research, manufacturing, and marketing of branded formulations and healthcare products. The company serves over 100,000 doctors and 400,000 pharmacies globally across 13 countries. It is known for its quality, accessibility, and innovation-driven approach, led by CEO Ashish Bhuta and CFO Dilip Bhuta, and supported by a team of 850+ professionals.
Key Highlights:
- Incorporated: 1985
- Headquarters: Mumbai, Maharashtra, India
- CEO: Ashish Bhuta
- Employees: 850+
- Global Presence: 13 countries
- Public Listing: BSE (Ticker: 524731)
- Market Cap (July 2025): ~₹574 crore
- Share Price (July 2025): ₹1,303.9
2. Products and Services
Jenburkt offers a portfolio of over 85 branded pharmaceutical and healthcare products across multiple therapeutic areas:
Pharmaceutical Formulations:
- Prescription drugs for pain, infections, neuropathy, diabetes, arthritis, acidity, malaria, and more
- Consumer healthcare products like nutritionals, vitamins, and protein supplements
Notable Brands:
- Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, Glucotrol, Hybrita, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, Pantazole, Piritexyl, Powergesic, Rabera, Topcal-M, Trapidol-D, Zenglobin, ZIXA, and others
Distribution & Services:
- 1,000+ stockists supporting wide retail and institutional coverage
- Over 100,000 doctors and 400,000 pharmacies served
- Active in government institutions and exports across 13 countries
- Custom manufacturing and institutional supply services
Jenburkt regularly engages with the medical community and invests in R&D to support brand growth and therapeutic innovation.
3. Recent News and Financial Performance
Business Developments:
- Strengthened focus on non-operating income, brand building, and portfolio expansion
- No major M&A activity, but ongoing R&D and market development initiatives
- February 2025 – Support to NIMHANS Neuropathy Series: Jenburkt sponsored the Neuropathy Lecture Series by NIMHANS to train primary care physicians across India in neuropathy diagnosis and treatment using telemedicine.
- Expanded CNS Portfolio and Medical Outreach: Portfolio enhancement in the neurology segment with brands like Gabrica and Gabantin, and stepped-up medical education via workshops and advisory boards
4. Financial Performance (FY2025)
| Metric | FY2025 Value |
|---|---|
| Total Revenue | ₹152 crore |
| Net Profit | ₹32 crore |
| Earnings Per Share (EPS) | ₹72.64 |
| Operating Profit Margin | 26.6% |
| Net Profit Margin | 21% |
| Return on Equity (ROE) | 20% |
| Dividend Payout % | 25% |